Bottom Line:
Researchers compared the selective serotonin reuptake inhibitor (SSRI) fluoxetine with placebo for reducing the frequency and severity of obsessive-compulsive behaviors in children and adolescents with autism spectrum disorder (ASD) in this randomized clinical trial in Australia. The trial included 146 participants (ages 7 to 18) with ASDs; 75 received fluoxetine and 71 received placebo for 16 weeks. Of the participants, 109 completed the trial. The authors report that for the primary outcome (total scores on an obsessive-compulsive scale modified for pervasive developmental disorder) treatment with fluoxetine compared with placebo resulted in lower scores for obsessive-compulsive behaviors but the interpretation of that finding is limited by a number of factors. These factors include the study’s high dropout rate and significant differences found between groups in some measures at baseline.
To access the embargoed study:
Visit our For The Media website at this link
https:/
/
media.
jamanetwork.
com/
Authors:
Dinah S. Reddihough, M.D., of the Royal Children’s Hospital, Melbourne, Australia, and coauthors.
(doi:10.1001/jama.2019.14685)
Editor’s Note:
The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
Media advisory:
To contact corresponding author Dinah S. Reddihough, M.D., email
[email protected]
. The full study and editorial are linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https:/
/
jamanetwork.
com/
journals/
jama/
fullarticle/
10.
1001/
jama.
2019.
14685?guestAccessKey=
51958aff-a578-4f40-8196-0293f4d957b7&utm_source=
For_The_Media&utm_medium=
referral&utm_campaign=
ftm_links&utm_content=
tfl&utm_term=
102219
###
This part of information is sourced from https://www.eurekalert.org/pub_releases/2019-10/jn-tcs101719.php
Dinah S. Reddihough, M.D.
[email protected]
@JAMA_current